Development history of CAR-T cell therapy 

The development of CAR-T cell therapy can be traced back to 1989, when Cross G and three other scientists first proposed the concept of "CAR". Then, in 2008, the Fred Hutchison Cancer Institute first used CAR T cells to treat B-cell lymphoma, demonstrating the safety of this therapeutic method. In 2010, the first successful case of CD19-targeting CAR-T therapy for B-cell-associated non-Hodgkin lymphoma was reported in the United States. Then in 2011, Professor Carl June's study at the University of Pennsylvania made significant progress, and Emily's successful treatment story, prompted CAR T immune cell therapy has entered a new period of explosion. In 2017, the US Food and Drug Administration (FDA) approved the marketing authorization of the first CAR T cell product Kymriah, which marked the arrival of the commercial era of CAR T cells. In the same year, Yescarta, the second CAR-T immune cell therapy product, was also approved for marketing authorization. In 2020, the FDA approved a third CAR T-cell therapy product Tecartus. In 2021, the FDA approved two CAR-T immunotherapy products, Breyanzi and Abecma, for the treatment of refractory or relapsing large B-cell lymphoma and multiple myeloma, respectively. In the same year, CDE from China also approved the marketing authorization of two CAR T immune cell therapy products from Axi-Cel and relma-cel, both for the treatment of adult patients with refractory or recurrent large B-cell lymphoma.

In 2022, the FDA approved the marketing authorization of Carvykti, a CAR-T cell therapy product targeting B cell maturation antigen (BCMA) for the treatment of relapsed or refractory multiple myeloma.

At this point, CAR T cell therapy has entered the era of cancer immunotherapy and opened a gorgeous prelude in the world.

What is CAR-T cell therapy

CAR T cell therapy, also known as Chimeric antigen receptor T cellI immunotherapy (CAR-T), is a tumor immunotherapy that uses genetic engineering to modify T cells in vitro. This allows them to specifically recognize tumor cells and inject those cells back into the patient to treat the disease.